Foghorn Therapeutics Holds Successful Annual Meeting

Foghorn Therapeutics ( (FHTX) ) has provided an announcement.

On June 17, 2025, Foghorn Therapeutics Inc. held its Annual Meeting of Stockholders, where all proposals were approved, including the election of four Class II directors for a three-year term and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The successful approval of these proposals signifies strong shareholder support and positions the company for continued governance stability and financial oversight.

The most recent analyst rating on (FHTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.

Spark’s Take on FHTX Stock

According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.

Foghorn Therapeutics’ overall score is primarily impacted by its financial difficulties and negative valuation metrics. However, positive corporate developments and some short-term technical momentum provide a degree of optimism. Significant improvements in financial performance and stability are necessary for a more favorable outlook.

To see Spark’s full report on FHTX stock, click here.

More about Foghorn Therapeutics

Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for cancer and other serious diseases. The company leverages its proprietary Gene Traffic Control platform to discover and develop novel treatments.

Average Trading Volume: 123,934

Technical Sentiment Signal: Sell

Current Market Cap: $244.7M

For a thorough assessment of FHTX stock, go to TipRanks’ Stock Analysis page.